We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Filters

Equity Crowdfunding Pitches

Showing results
Muse is a smart, data-driven financial management application which aims to make financial empowerment a reality for all business owners. The app generates clear snapshots of a company’s finances showing all bank balances, and gives quick access to innovative invoice financing and other smart tools. Muse is live on the App Store and Google Play. Moreover, it has partnered with Prime 5 Finance Limited for invoice finance facility. The funds raised will be used to expand the business, sales channels and give an e-money account card in three currencies.

Pitch Rated

36%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £339,920
Celo is an app-based insurance provider designed to provide cheaper quotes, faster claims, and a pleasant user experience. We plan to offer insurance cover for motor vehicles, travel, health, and more. Like Monzo and Starling who are disrupting banking, Celo plans to disrupt the insurance industry.

Pitch Rated

39%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £142,840
MyT is a cloud-powered subscription-based accounting software designed for small businesses that allows them to submit financial information to Her Majesty's Revenue and Customs (HMRC) under the Making Tax Digital initiative, which is mandatory from April 2023. MyT asserts that its app provides businesses with a simple way to keep track of business finances on the go, send and manage invoices and bills, and record expenses and mileage. The company claims that its app is available on App Store and Google Play and has witnessed 1000+ downloads to date. It claims that it has onboarded over 500 users without any extensive marketing spend. MyT will use half of the investment to implement its marketing plan, a third for developing new technology and the remaining for administrative expenses.

Pitch Rated

73%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £133,543
A decentralised banking platform with already more than £13.5m dedicated for software development. BABB intends to become a licensed bank in the UK and is raising funds for the capital required to do so. The company aims to allow anyone access to a bank account, as well as a mobile app for customers to make payments, lend money and exchange currencies.

Pitch Rated

66%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,362,430
AxiaFunder is a commercial litigation funding platform that offers investors access to pre-vetted cases. The platform aims to connect eligible investors like sophisticated retail investors, high-net-worth, and typically institutions with claimants seeking funding. Launched in January 2019 with the first case fully funded within seven days and the third in 7 hours; 5 cases financed to date, attracted over 355 registered investors so far including several institutions and has featured in several prominent publications including the Financial Times, Times and City AM. Also, they have won the 'Best Commercial Litigation Crowdfunding Platform 2019' award by Wealth & Finance. AxiaFunder plans to use the proceeds to make key hires particularly to strengthen its case origination, further development of its platform and marketing to build the AxiaFunder brand and grow its investor base.

Pitch Rated

72%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £256,780
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £532,311
EnXray are developing Low Energy X-ray (LEXR) technologies to sterilise equipment in commercial or research settings where low volume/high value therapeutic products, such as cancer vaccines and stem cell implants are being developed. Their aim is to reduce the need for third party providers and have the sterilisation process done on-site and on-demand with simple and safe equipment to reduce cost and save time for medical research organisations.

Pitch Rated

61%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £376,230
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones and helps people decide how much insulin to take and when. They are on a mission to help people with insulin-treated diabetes make the best possible decisions through their app. The company have received a UK research and innovation grant. Apple has granted them insider access to their engineers and executives who are helping to get Quin to market, their app has a class I CE Mark, with two patents pending. With the investment, they will hire a product designer to enhance the user experience, achieve certification and compliance with new European Medical Device Regulations, develope B2B2C distribution partnerships and launch the Quin app in the UK and Europe in late 2020.

Pitch Rated

48%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £691,497
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £200,000
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph